Commence Bio is a therapeutics company that is developing methods to enhance the anti-inflammatory properties of stem cells. The company aims to apply these methods in various inflammation-related disorders that include rheumatoid arthritis, by creating cellular therapeutics with predictable behaviors.
The company's technology is used to change adult, allogeneic mesenchymal stem cells into powerful immunomodulators that migrate to the sites of immune dysfunction through a multi-pronged effect and re-awakening the body's innate and adaptive immune responses, allowing patients to get treatments for cancer and inflammatory diseases by rebooting the immune systems of patients with cell therapies.
Commence Bio has the vision that cancer and inflammatory diseases can be treated by rebooting patients' immune systems with a new class of medicinal stem cells: MSC1 & MSC2. Using its proprietary Stimulated Toll-like Receptor Technology [STaRT™], adult, allogeneic mesenchymal stem cells [MSCs] are transformed into powerful immunomodulators that migrate to the sites of dysfunction and. through a multi-pronged effect, reboot an appropriate immune response.
Co-Founder & CEO
Commence Bio Finalizes Corporate Identity Change From WibiWorks Therapeutics and Introduces New Website
Commence Bio Receives 1st Patent for MSC1: A New Cancer Immunotherapy Platform
Commence Bio, Inc.
Commence Bio to Present at 2016 Cell & Gene Meeting on the Mesa
Commence Bio, Inc.
Novel Cancer Immunotherapy Technology by Commence Bio Receives Patent - Immuno-Oncology News
Documentaries, videos and podcasts
October 22, 2015
- BiotechnologyBiotechnology can refer to the application of science and technology to living organisms or the use of living organisms, their parts, products or models thereof to solve a problem, produce knowledge or produce goods and services. Biotechnology may involve the alteration of living or non-living materials.
- ImmunotherapyImmunotherapy aims to treat disease through activation or suppression of an immune response. For example activating immunotherapies can target cancer and suppressive immunotherapies can target autoimmunity.